Literature DB >> 21298219

Role of re-resection in non-muscle-invasive bladder cancer.

Harry W Herr1.   

Abstract

Restaging, or second transurethral resection (TUR), is essential to successful management of high-risk, non-muscle-invasive bladder cancer. Here we review the relevant literature documenting the role of restaging TUR. Cohort and randomized studies show that restaging TUR detects more tumors than initial TUR, improves clinical staging, and reduces the frequency of early tumor recurrences. Our conclusions show thatrestaging TUR improves the outcomes of high-risk,non-muscle-invasive bladder neoplasms.

Entities:  

Mesh：

Year:  2011        PMID： 21298219      PMCID： PMC5720095          DOI： 10.1100/tsw.2011.29

Source DB:  PubMed          Journal:  ScientificWorldJournal        ISSN： 1537-744X


  9 in total

1.  The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin.

Authors:  Paolo Gontero; Richard Sylvester; Francesca Pisano; Steven Joniau; Marco Oderda; Vincenzo Serretta; Stéphane Larré; Savino Di Stasi; Bas Van Rhijn; Alfred J Witjes; Anne J Grotenhuis; Renzo Colombo; Alberto Briganti; Marek Babjuk; Viktor Soukup; Per-Uno Malmström; Jacques Irani; Nuria Malats; Jack Baniel; Roy Mano; Tommaso Cai; Eugene K Cha; Peter Ardelt; John Vakarakis; Riccardo Bartoletti; Guido Dalbagni; Shahrokh F Shariat; Evanguelos Xylinas; Robert J Karnes; Joan Palou
Journal:  BJU Int       Date:  2015-11-06       Impact factor: 5.588

2.  Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.

Authors:  Takuya Koie; Chikara Ohyama; Shogo Hosogoe; Hayato Yamamoto; Atsushi Imai; Shingo Hatakeyama; Takahiro Yoneyama; Yasuhiro Hashimoto; Tohru Yoneyama; Yuki Tobisawa; Kazuyuki Mori
Journal:  Int Urol Nephrol       Date:  2015-07-07       Impact factor: 2.370

3.  Utility of the EORTC risk tables and CUETO scoring model for predicting recurrence and progression in non-muscle-invasive bladder cancer patients treated with routine second transurethral resection.

Authors:  Guoxian Zhang; Daniel Steinbach; Marc-Oliver Grimm; Marcus Horstmann
Journal:  World J Urol       Date:  2019-03-25       Impact factor: 4.226

4.  Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought.

Authors:  J Palou; F Pisano; R Sylvester; S Joniau; V Serretta; S Larré; S Di Stasi; B van Rhijn; A J Witjes; A Grotenhuis; R Colombo; A Briganti; M Babjuk; V Soukup; P U Malmstrom; J Irani; N Malats; J Baniel; R Mano; T Cai; E K Cha; P Ardelt; J Varkarakis; R Bartoletti; G Dalbagni; S F Shariat; E Xylinas; R J Karnes; P Gontero
Journal:  World J Urol       Date:  2018-05-02       Impact factor: 4.226

Review 5.  Approaching the optimal transurethral resection of a bladder tumor.

Authors:  Michael Jurewicz; Mark S Soloway
Journal:  Turk J Urol       Date:  2014-06

6.  Tumour stage on re-staging transurethral resection predicts recurrence and progression-free survival of patients with high-risk non-muscle invasive bladder cancer.

Authors:  Mohamed Bishr; Jean-Baptiste Lattouf; Mathieu Latour; Fred Saad
Journal:  Can Urol Assoc J       Date:  2014-05       Impact factor: 1.862

Review 7.  Emerging endoscopic and photodynamic techniques for bladder cancer detection and surveillance.

Authors:  Prashant Patel; Richard T Bryan; D Michael A Wallace
Journal:  ScientificWorldJournal       Date:  2011-12-29

Review 8.  Transurethral resection of bladder tumour (TURBT).

Authors:  Lawrence H C Kim; Manish I Patel
Journal:  Transl Androl Urol       Date:  2020-12

9.  Risk Stratification for the Rate and Location of Residual Bladder Tumor for the Decision of Re-Transurethral Resection of Bladder Tumor.

Authors:  Junjie Fan; Xing Zhang; Jinhai Fan; Lei Li; Dalin He; Kaijie Wu
Journal:  Front Oncol       Date:  2022-01-27       Impact factor: 6.244
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.